Polatuzumab vedotin (solution)
Product Specifications
UNSPSC Description
Polatuzumab vedotin solution is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin solution has the potential for the research of Large B-cell lymphomas (LBCL)[1].
Target Antigen
Antibody-Drug Conjugates (ADCs)
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/polatuzumab-vedotin-solution.html
Smiles
[Polatuzumab vedotin (solution)]
References & Citations
[1]Liebers N, et al. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. Blood Adv. 2021 Jul 13;5(13):2707-2716.|[2]Li D, et al. Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin. Br J Pharmacol. 2019 Oct;176(19):3805-3818.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-132253A/Polatuzumab-vedotin-solution-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-132253A/
Clinical Information
No Development Reported
CAS Number
1313206-42-6
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1006977-01 0.02 mg (E-Coli)
Recombinant Pseudomonas aeruginosa Aspartyl/glutamyl-tRNA (Asn/Gln) amidotransferase subunit C
Ask
View Details